keyword
MENU ▼
Read by QxMD icon Read
search

ASCO

keyword
https://www.readbyqxmd.com/read/29333022/2017-asco-highlights-on-gastointestinal-malignancies
#1
Ravi Kumar Paluri
No abstract text is available yet for this article.
October 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/29332134/breast-cancer-survivorship-state-of-the-science
#2
REVIEW
Kathy Pan, Arti Hurria, Rowan T Chlebowski
PURPOSE: Only recently has breast cancer survivorship earned formal recognition as a research discipline. Complicating survivorship research is the frequent overlap between aging and treatment sequelae. The ACS/ASCO 2016 Breast Cancer Survivorship Care Guideline (Guideline) reflects comprehensive literature review through April 2015, while the jointly sponsored, inaugural Cancer Survivorship Symposium in 2016 (Symposium) reflects ongoing research activity in the area. Together, these platforms provide an opportunity to examine the use of randomized trials and controlled studies in survivorship care research...
January 13, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29328775/breast-specimen-processing-and-reporting-with-an-emphasis-on-margin-evaluation
#3
Anthony J Guidi, Joseph A Tworek, Daniel D Mais, Rhona J Souers, Barbara J Blond, Richard W Brown
CONTEXT: The College of American Pathologists (CAP) developed protocols for reporting pathologic characteristics of breast cancer specimens, including margin status. The Society of Surgical Oncology (SSO) and the American Society for Radiation Oncology (ASTRO) published treatment guidelines regarding margins in patients with invasive cancer; and SSO, ASTRO, and the American Society of Clinical Oncology (ASCO) recently published guidelines for patients with ductal carcinoma in situ. OBJECTIVE: - To assess current practices among pathologists with regard to the processing/reporting of breast specimens, assess compliance with CAP cancer protocols, and assess alignment with SSO/ASTRO and SSO/ASTRO/ASCO guidelines...
January 12, 2018: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/29298114/oncology-pharmacist-opportunities-closing-the-gap-in-quality-care
#4
Vera Vulaj, Shannon Hough, Louise Bedard, Karen Farris, Emily Mackler
PURPOSE: ASCO has worked to facilitate the improvement in quality oncology care via the development of the Quality Oncology Practice Initiative (QOPI). The extent to which the ASCO QOPI identifies areas in which pharmacists may enhance care is not known. These findings are important, as pharmacists are an integral part of the care team, providing direct clinical care in addition to medication use guidelines and practice-based policies. In addition, high-performing practices may receive reimbursement from the Centers for Medicare and Medicaid Services...
January 3, 2018: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29297903/-pembrolizumab-for-the-treatment-of-melanoma-updates-and-perspectives
#5
Vanna Chiarion Sileni, Mario Mandalà, Paola Queirolo
Checkpoint inhibitors immunotherapy was a breakthrough in anti-tumor treatments. Anti-PD-1 monoclonal antibodies are now a standard of treatment for advanced melanoma patients, with a 3-year overall survival of over 50% and a low rate (<20%) of severe toxicities in the phase 3 studies. The aim of this review was to report the most important updates on anti-PD-1 drug pembrolizumab from ASCO (American Society of Clinical Oncology) and ESMO (European Society for Medical Oncology) 2017 Annual Meetings.
December 2017: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/29297896/-let-s-go-forward-but-wisely%C3%A2
#6
Massimo Di Maio
In recent years, the oncologic community has been widely debating the high costs of new anti-cancer drugs, that put at risk the sustainability of the health care system. In a study published in BMJ in October 2017, Davis and colleagues analyzed clinical trials conducted with anti-cancer drugs approved by the European Medicines Agency between 2009 and 2013. The authors emphasized that most anti-cancer drugs have been approved without any evidence of an improvement in overall survival and/or in quality of life...
December 2017: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/29290169/evaluating-oncology-value-based-frameworks-in-the-u-s-marketplace-and-challenges-in-real-world-application-a-multiple-myeloma-test-case
#7
Laurence M Djatche, Joseph A Goble, Grace Chun, Stefan Varga
BACKGROUND: With the continuous rise in costs for oncology drugs, the American Society of Clinical Oncology (ASCO), the Institute for Clinical and Economic Review (ICER), the Memorial Sloan Kettering Cancer Center's Drug Abacus (DrugAbacus), and the National Comprehensive Cancer Network (NCCN) have developed value-based frameworks (VBFs) to assist stakeholders in formulary and treatment decision-making processes. Since emerging VBFs have the potential to affect available treatment options for patients, it is important to understand the differences associated with these VBFs within various therapeutic areas...
January 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29285547/association-of-immunotherapy-with-durable-survival-as-defined-by-value-frameworks-for-cancer-care
#8
Omer Ben-Aharon, Racheli Magnezi, Moshe Leshno, Daniel A Goldstein
Importance: Modern immuno-oncology agents have generated great excitement because of their potential to provide durable survival for some patients. However, there is concern regarding the cost of cancer care, and multiple frameworks have been developed to assess value. The American Society of Clinical Oncology (ASCO) framework awards bonus points if substantial durable survival is demonstrated. Objective: To assess whether modern immuno-oncology agents reach defined efficacy thresholds in value frameworks...
December 28, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29273089/famitinib-versus-placebo-in-the-treatment-of-refractory-metastatic-colorectal-cancer-a-multicenter-randomized-double-blinded-placebo-controlled-phase-ii-clinical-trial
#9
Rui-Hua Xu, Lin Shen, Ke-Ming Wang, Gang Wu, Chun-Mei Shi, Ke-Feng Ding, Li-Zhu Lin, Jin-Wan Wang, Jian-Ping Xiong, Chang-Ping Wu, Jin Li, Yun-Peng Liu, Dong Wang, Yi Ba, Jue-Ping Feng, Yu-Xian Bai, Jing-Wang Bi, Li-Wen Ma, Jian Lei, Qing Yang, Hao Yu
BACKGROUND: Metastatic colorectal cancer (mCRC) patients with progressive disease after all available standard therapies need new medication for further treatment. Famitinib is a small-molecule multikinase inhibitor, with promising anticancer activities. This multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial was designed to evaluate the safety and efficacy of famitinib in mCRC. METHODS: Famitinib or placebo was administered orally once daily...
December 22, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/29260622/surrogate-end-points-for-overall-survival-in-trials-of-pd-l-1-inhibitors-for-urinary-cancers-a-systematic-review
#10
Omar Abdel-Rahman
AIM: Numerous trials for PD-(L)1 inhibitors in the management of advanced urinary cancers (urothelial carcinoma and renal cell carcinoma) were published recently. It is not known exactly what should be the optimal surrogate end point for overall survival (OS) in this context. MATERIALS & METHODS: PubMed database and ASCO meeting library were searched till August 2017. Eligible studies included prospective clinical studies evaluating PD-(L)1 inhibitors for the management of advanced urothelial carcinoma or renal cell carcinoma...
February 2018: Immunotherapy
https://www.readbyqxmd.com/read/29251392/impact-of-2013-asco-cap-her2-reporting-guidelines-in-breast-cancer-an-assessment-study-from-indian-oncology-centre-that-primarily-performs-her2-ihc-testing-with-special-emphasis-on-ihc-equivocal-category
#11
Sunil Pasricha, Gurudutt Gupta, Ritu Garg, Anila Sharma, Jatin S Gandhi, Garima Durga, Meenakshi Kamboj, Shrruti Grover, Anurag Mehta
The ASCO/CAP guidelines for HER2 reporting in breast cancer published in 2007 and were updated in 2013 to assure that the right patient receives the targeted therapy. The updated guidelines have lowered the threshold for HER2 positivity criteria and altered the equivocal category for both IHC and FISH. This first study from India addresses the impact of these updated guidelines in the various reporting categories at a tertiary care centre. We compared the trend of HER2 IHC reporting 1 year before (Period A) and 1 year after (Period B) the implementation of updated 2013 ASCO/CAP guidelines...
December 18, 2017: Breast Journal
https://www.readbyqxmd.com/read/29251165/prostate-cancer-high-dose-rate-brachytherapy-review-of-evidence-and-current-perspectives
#12
Sunil W Dutta, Clayton E Alonso, Bruce Libby, Timothy N Showalter
Patients with intermediate to high risk disease (prostate specific antigen (PSA) ≥ 10, Gleason score ≥ 7, or clinical stage ≥ T2b) suffer from poorer long-term biochemical control (freedom from an increasing prostate specific antigen level) when treated with external beam radiation (EBRT) alone. In order to improve biochemical control while limiting long-term complications, brachytherapy has been incorporated into radiotherapy treatment, either alone or in combination with EBRT. Areas covered: Current literature regarding the use of high dose-rate (HDR) brachytherapy for localized prostate cancer, including as a boost and monotherapy...
December 22, 2017: Expert Review of Medical Devices
https://www.readbyqxmd.com/read/29250204/asco-update-gastrointestinal-tumors
#13
REVIEW
Lukas Weiss, Florian Huemer, Richard Greil
A multitude of new molecular and immunologic insights into gastrointestinal tumors have been presented at the ASCO meeting 2017; however, we have focused our update on practice-changing phase 3 trials and tried to set them into clinical perspective. Furthermore, we will elaborate on updated data on immunotherapeutics in gastroesophageal cancers, since drug approvals may be anticipated before convening for the next meeting in 2018.
2017: Memo
https://www.readbyqxmd.com/read/29250203/asco-2017-highlights-of-gynecological-cancer
#14
REVIEW
Bianca Radl, Brigitte Mlineritsch
At this year's ASCO annual meeting several important studies in the field of gynecological cancer were presented. Here we report a personal selection of the most interesting and clinically relevant data.
2017: Memo
https://www.readbyqxmd.com/read/29250202/asco-2017-highlights-in-breast-cancer
#15
REVIEW
Rupert Bartsch, Elisabeth Bergen
At the 2017 ASCO Annual Meeting, several pertinent studies in the field of breast cancer were presented and some are deemed as being potentially practice changing. BrighTNess was the first phase III study to investigate the addition of carboplatin to standard neoadjuvant chemotherapy in triple-negative breast cancer; while toxicity was increased in the experimental group, a significantly higher pathologic complete remission (pCR) rate was observed as well suggesting that adding carboplatin to neoadjuvant anthracycline, cyclophosphamide and taxane-containing regimens is efficacious in otherwise healthy patients...
2017: Memo
https://www.readbyqxmd.com/read/29250201/asco-update-lung-cancer
#16
REVIEW
Gudrun Absenger, Jasmin Terzic, Angelika Bezan
In the past few years there have been major changes in the treatment landscape in oncology; lung cancer is affected by those changes like almost no other solid tumor. The rise of further second- and third-line tyrosine kinase inhibitors offers sequential therapy for patients with mutated non-small-cell lung cancer. Immunotherapy has found its way into clinical routine and presents us with new challenges in managing side effects, evaluating treatment response and deciding on how long we treat our patients. The treatment algorithm of lung cancer has changed in the last month and further practice-changing trials are coming up, so treating lung cancer patients shows nowadays a more challenging perspective with the possibility of subsequently applied individual therapies...
2017: Memo
https://www.readbyqxmd.com/read/29250200/update-on-squamous-cell-carcinoma-of-the-head-and-neck-asco-annual-meeting-2017
#17
REVIEW
Teresa Magnes, Alexander Egle, Richard Greil, Thomas Melchardt
At the annual ASCO meeting clinically relevant data concerning the management of advanced head and neck cancer that will influence clinical practice in the future were presented. Chemoradiation with high-dose cisplatin remains the mainstay of treatment for patients with locally advanced squamous cell head and neck cancer. Adjuvant therapy with afatinib following chemoradiation failed to show clinical benefit. The combination of bevacizumab with platinum-based chemotherapy improved progression-free survival but did not lead to a significant difference in overall survival compared to chemotherapy alone...
2017: Memo
https://www.readbyqxmd.com/read/29250199/asco-update-on-lymphoma
#18
REVIEW
Michael A Fridrik
s concerning indolent and aggressive lymphoma and multiple myeloma with clinical relevance from the ASCO 2017 meeting are discussed.
2017: Memo
https://www.readbyqxmd.com/read/29239191/-advances-in-immunotherapy-of-malignant-melanoma
#19
I Krajsová
Development of immunotherapy has dramatically changed poor prognosis of metastatic malignant melanoma (MM). Inhibition of immune checkpoints represents a new effective treatment. Monoclonal antibodies against CTLA-4 ipilimumab and against PD-1 (programme death 1) nivolumab and pembrolizumab prolong progression free survival and overall survival (OS) in patients with advanced metastatic MM. Both achieved significant improvement in relapse-free survival and OS also in adjuvant setting. It looks like the efficacy of the combined immunotherapy of ipilimumab with anti-PD-1 antibodies is superior to the monotherapy, but combined therapy is accompanied by higher toxicity...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/29236202/sentinel-lymph-node-biopsy-and-management-of-regional-lymph-nodes-in-melanoma-american-society-of-clinical-oncology-and-society-of-surgical-oncology-clinical-practice-guideline-update
#20
Sandra L Wong, Mark B Faries, Erin B Kennedy, Sanjiv S Agarwala, Timothy J Akhurst, Charlotte Ariyan, Charles M Balch, Barry S Berman, Alistair Cochran, Keith A Delman, Mark Gorman, John M Kirkwood, Marc D Moncrieff, Jonathan S Zager, Gary H Lyman
PURPOSE: To update the American Society of Clinical Oncology (ASCO)-Society of Surgical Oncology (SSO) guideline for sentinel lymph node (SLN) biopsy in melanoma. METHODS: An ASCO-SSO panel was formed, and a systematic review of the literature was conducted regarding SLN biopsy and completion lymph node dissection (CLND) after a positive sentinel node in patients with melanoma. RESULTS: Nine new observational studies, two systematic reviews and an updated randomized controlled trial (RCT) of SLN biopsy, as well as two randomized controlled trials of CLND after positive SLN biopsy, were included...
December 13, 2017: Annals of Surgical Oncology
keyword
keyword
33466
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"